About the RTX-240
phase 1/2 clinical trial
This Phase 1/2 clinical trial is designed to establish whether RTX-240 administered as monotherapy is safe, whether RTX-240 administered with pembrolizumab is safe, how much RTX-240 needs to be given as monotherapy or in combination for it to be effective, how often it should be given to be effective, and if RTX-240 has anti-tumor activity against the cancer. The trial seeks to evaluate:
The study drug, study-related services, supplies, procedures, and care performed as part of this study and not part of your routine medical care will be paid for by the study site, through the study Sponsor.
Who can participate?
Upon reviewing the clinical trial eligibility criteria, speak with your doctor about any questions you may have and clinical trials that may benefit you.
Adults who meet the following criteria may be able to participate in the trial. We cannot guarantee all those who qualify will be selected.
For the solid tumor monotherapy arm of the trial:
Participants in the trial will
undergo:
Patients will receive RTX-240 until the time in which the disease progresses or in the event of undesirable toxicities.
During the first week, patients will come in for the first three days, and then weekly for the rest of the cycle.
In cycle one, after the first three days, weekly visits are required.
In subsequent cycles, patients come in on day one of dosing and day three, followed by weekly visits.
Dosing days take approximately four to six hours, with subsequent visits to take approximately one hour.
The Angeles Clinic & Research Institute
Los Angeles, California,
United States, 90025
Contact: Saba Mukarram
310-231-2181
Columbia University Medical Center
New York, New York,
United States, 10032
Contact: Research Nurse Navigator
212-342-5162
Massachusetts General Hospital
Boston, Massachusetts,
United States, 02114
Contact: Ryan Sullivan, MD
617-724-5197
Oregon Health & Sciences University – Knight Cancer Institute
Portland, Oregon,
United States, 97239
Contact: Knight Cancer Institute Clinical Trials
Sarah Cannon Research Institute
Nashville, Tennessee,
United States, 37203
Contact: Sarah Cannon Research Site
615-329-7478
Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida,
United States, 33136
Contact: Jaime Merchan, MD
305-243-1287
Virginia Cancer Specialists
Fairfax, Virginia,
United States, 22031
Contact: Alexander Spira, MD, PhD, FACP
703-280-5390
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania,
United States, 15232
Contact: Sarah Brodeur
412-623-2944
University of California San Diego
La Jolla, California,
United States, 92093
Contact: Sandip Patel, MD
585-822-6477
Sarah Cannon Research Institute/Colorado Blood Cancer Institute
Denver, Colorado,
United States, 80218
Contact: Sarah Cannon Research Institute
844-482-4812
Thomas Jefferson University
Philadelphia, Pennsylvania,
United States, 19107
Contact: Usama Gergis, MD
215-955-4367
For the solid tumor RTX-240 in combination with KEYTRUDA® (pembrolizumab)1 arm of the trial:
Participants in the trial will undergo:
Patients will receive RTX-240 and pembrolizumab until the time in which the disease progresses or in the event of undesirable toxicities.
During the first week, patients will come in for the first three days, and then weekly for the rest of the cycle.
In cycle one, after the first three days, weekly visits are required.
In subsequent cycles, patients come in on day one of dosing and day three, followed by weekly visits.
Dosing days take approximately four to six hours, with subsequent visits to take approximately one hour.
Sarah Cannon Research Institute
Nashville, Tennessee,
United States, 37203
Contact: Sarah Cannon Research Site
615-329-7478
The Angeles Clinic & Research Institute
Los Angeles, California,
United States, 90025
Contact: Saba Mukarram
310-231-2181
Virginia Cancer Specialists
Fairfax, Virginia,
United States, 22031
Contact: Alexander Spira, MD, PhD, FACP
703-280-5390
Sarah Cannon Research Institute / Colorado Blood Cancer Institute
Denver, Colorado,
United States, 80218
Contact: Sarah Cannon Research Institute
844-482-4812
Thomas Jefferson University
Philadelphia, Pennsylvania,
United States, 19107
Contact: Usama Gergis, MD
215-955-4367
References: